Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose intraprostatic Liproca Depot (2-hydroxyflutamide) in localized prostate cancer
2011-001137-16Phase 2Terminated
- Sponsor
- LIDDS AB
- Start
- Mar 2011
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 2-hydroxyflutamide depot in prostate cancer (PCa), sponsored by LIDDS AB. Primary endpoints: Histopathological changes in surgical specimens and Imaging changes on MRI. Started Mar 2011; status: terminated.
02
Drugs
2-hydroxyflutamide depot
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2011-001137-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001137-16.